NCT04726618|Terminated
Study Stopped
Funding constraints
Loading search results
Funding constraints
Sponsor study identifier
observational
24
1 country
1
Study Start
March 1, 2022
Actual (reported)Primary Completion
April 9, 2024
Actual (reported)Study Completion
April 9, 2024
Actual (reported)This is a single centre study. The overarching hypothesis of this study is that MRI with inhaled tracer gases can provide high quality images of lung function to complement conventional 1H MRI. The study interventions do not affect the standard of care.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 9, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 22, 2021
Actual (reported)January 27, 2021
Actual (reported)March 1, 2022
Actual (reported)April 9, 2024
Actual (reported)April 9, 2024
Actual (reported)The primary objective of this study is to develop the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high quality lung images using HP 129Xe, 19F MRI, and conventional 1H MRI.
This objective will initially begin with preliminary work to demonstrate the ability to acquire in vivo 129Xe and/or 19F MR images in participants with no history of respiratory disease. This study will also focus on the advancement of MR imaging hardware and software to optimize image acquisition and reconstruction. Imaging capability will be evaluated on the basis of image quality, signal-to-noise ratio, contrast-to-noise ratio, image resolution, and scan duration. We will also explore new methods of generating image contrast with these gases.
5 years
Comparison of 19F MRI to HP 129Xe MRI
5 years
Evaluation of intra and inter-scan reproducibility
5 years
Comparison of MR imaging to pulmonary function testing
5 years
Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity. Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Hyperpolarized 129-xenon gas and Perfluoropropane gas
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record50 male and females aged 6-75 with no history of respiratory disease will be used for this study.
Hospital for Sick Children
Toronto, Ontario, M5G 0A4, Canada
Giles Santyr, PhD
The Hospital for Sick Children
24 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2021
First Posted
January 27, 2021
Study Start
March 1, 2022
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
April 9, 2024
Actual (reported)Study Completion
April 9, 2024
Actual (reported)Last Updated
September 4, 2025
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: